| Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report Remap-Cap Investigators, AC Gordon, PR Mouncey, F Al-Beidh, ... MedRxiv, 2021.01. 07.21249390, 2021 | 1456 | 2021 |
| Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19 ATTACC, ACTIV-4a, and REMAP-CAP Investigators New England Journal of Medicine 385 (9), 790-802, 2021 | 1153 | 2021 |
| Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial DC Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, ... Jama 324 (13), 1317-1329, 2020 | 887 | 2020 |
| Interleukin-6 receptor antagonists in critically ill patients with Covid-19 Remap-Cap Investigators New England Journal of Medicine 384 (16), 1491-1502, 2021 | 665 | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... JAMA 326 (6), 499-518, 2021 | 532 | 2021 |
| Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial H Abdelhady, M Abdelrazik, Z Abdi, D Abdo, A Abdulle, L Abel, ... Jama 326 (17), 1690-1702, 2021 | 209 | 2021 |
| Development and validation of machine learning models to identify high-risk surgical patients using automatically curated electronic health record data (Pythia): A … KM Corey, S Kashyap, E Lorenzi, SA Lagoo-Deenadayalan, K Heller, ... PLoS medicine 15 (11), e1002701, 2018 | 197 | 2018 |
| Long-Term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, A Kidwai, ... JAMA 329 (1), 39-51, 2023 | 121 | 2023 |
| Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial CA Bradbury, PR Lawler, SJ Stanworth, BJ McVerry, Z McQuilten, ... Jama 327 (13), 1247, 2022 | 102 | 2022 |
| Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial YM Arabi, AC Gordon, LPG Derde, AD Nichol, S Murthy, F Al Beidh, ... Intensive Care Medicine, 1-20, 2021 | 102 | 2021 |
| WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for … M Shankar-Hari, CL Vale, PJ Godolphin, D Fisher, JPT Higgins, F Spiga, ... Jama 326 (6), 499-518, 2021 | 71 | 2021 |
| Heterogeneous treatment effects of therapeutic-dose heparin in patients hospitalized for COVID-19 EC Goligher, PR Lawler, TP Jensen, V Talisa, LR Berry, E Lorenzi, ... Jama 329 (13), 1066-1077, 2023 | 69 | 2023 |
| A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high‐risk neuroblastoma EC Lewis, JM Kraveka, W Ferguson, D Eslin, VI Brown, G Bergendahl, ... International journal of cancer 147 (11), 3152-3159, 2020 | 51 | 2020 |
| Propensity Score Weighting for Causal Subgroup Analysis S Yang, E Lorenzi, G Papadogeorgou, DM Wojdyla, F Li, LE Thomas Statistics in Medicine; https://onlinelibrary.wiley.com/doi/10.1002/sim.9029, 2020 | 47 | 2020 |
| Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized … S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... JAMA 329 (14), 1183-1196, 2023 | 45 | 2023 |
| Simvastatin in critically ill patients with Covid-19 REMAP-CAP Investigators New England Journal of Medicine 389 (25), 2341-2354, 2023 | 35 | 2023 |
| Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: Externally controlled, propensity score–matched survival outcome comparisons J Oesterheld, W Ferguson, JM Kraveka, G Bergendahl, T Clinch, ... Journal of Clinical Oncology 42 (1), 90-102, 2024 | 28 | 2024 |
| Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... JAMA 330 (18), 1745-1759, 2023 | 25 | 2023 |
| Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis PJ Godolphin, DJ Fisher, LR Berry, LPG Derde, JV Diaz, AC Gordon, ... PloS one 17 (7), e0270668, 2022 | 25 | 2022 |
| Choice of dose level for a randomized clinical trial of low-dose bevacizumab vs laser for type 1 retinopathy of prematurity RT Kraker, DK Wallace, RW Beck, CT Saunders, E Lorenzi, BM Melia, Z Li, ... JAMA ophthalmology 139 (10), 1143-1144, 2021 | 9 | 2021 |
